| Date | Title | Description |
| 27.03.2026 | Global Crossroads: Pharma Shifts and Markets Sway | Wall Street navigates intense volatility. Geopolitical tensions from the ongoing Iran conflict drive market swings. Oil prices ease on perceived de-escalation, yet regional attacks persist. Global stocks post fragile gains. Amid this turbul... |
| 25.03.2026 | Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline | Merck will acquire Terns for $53 per share in cash, amounting to an equity value of about $6.7 billion.
This is the third multibillion-dollar acquisition for Merck over the past year as it looks to bulk up its portfolio ahead of its best-se... |
| 12.03.2026 | Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China | Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special Administrative Regions (SARs) in Greater China
SHANGHAI, March 12, 2026 /PRNewswire/... |
| 30.10.2025 | Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit | Merck reported third-quarter earnings and revenue that topped estimates in part due to strong demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook to reflect lower estimated tariff costs and other items.
S... |
| 04.08.2025 | After Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line? | Last month, Hengrui Pharmaceuticals announced a blockbuster licensing deal with GSK worth up to USD 12.5 billion, with an upfront payment of USD 500 million. The deal grants GSK the overseas rights to Hengrui’s HRS-9821 as well as exclusive... |
| 29.07.2025 | Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook | Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline.
The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming... |
| 10.07.2025 | Американский Merck покупает за $10 млрд британскую Verona Pharma | - |
| 10.07.2025 | Merck покупает Verona Pharma за $10 млрд | - |
| 09.07.2025 | Немецкая Merck приобретает производителя респираторных препаратов Verona Pharma за $10 млрд | Merck, штаб-квартира которой находится в Нью-Джерси, активно ищет сделки на фоне предстоящих потерь патентов, способных сократить её доходы на $18 млрд за следующие пять лет. Компания согласилась заплатить $107 за одну американскую депозита... |
| 09.07.2025 | Gains for tech stocks push Nasdaq to another record | Wednesday was initially set as a deadline by Trump for countries to make deals with the U.S. or face heavy increases in tariffs. But with just two trade deals announced since April, one with the United Kingdom and one with Vietnam, the wind... |
| 09.07.2025 | Merck spends $10 billion for Verona, gaining access to its COPD medication | Ohtuvayre was launched last August as the first commercial product for London-based Verona Pharma. The drug also is being studied as a possible treatment for another chronic respiratory problem that gets worse over time: non-cystic fibrosis... |
| 09.07.2025 | Stocks making the biggest moves midday: AES, Nvidia, Bloom Energy, Verona Pharma and more | - |
| 09.07.2025 | Merck to buy U.K.-based Verona Pharma for $10 billion | This is CNBC’s live blog covering European markets.
U.S. pharmaceutical firm Merck will purchase U.K.-based Verona Pharma for around $10 billion, the companies said Wednesday.
The move, which will help build out the firm’s respiratory treat... |
| 09.07.2025 | Merck to buy UK’s Verona Pharma for $10 billion in bid to diversify beyond cancer treatment | - |
| 09.07.2025 | Stocks making the biggest moves premarket: Starbucks, AES, Verona Pharma, UnitedHealth and more | - |
| 30.05.2025 | Cramer’s Lightning Round: A Market Pulse Check | In the fast-paced world of stock trading, few figures stand out like Jim Cramer. The host of CNBC's "Mad Money" has become a beacon for investors seeking guidance. His lightning round segments are a whirlwind of stock picks, insig... |
| 27.05.2025 |
Cramer’s Lightning Round: IONQ is ‘too speculative for me’ | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Valero Energy: “I’d rather be in the Philli... |
| 16.05.2025 | Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD | Statistically significant improvements in lung function
Consistent trends of quality of life and exacerbation rate reduction as ENHANCE-1/2
Well tolerated safety profile
NDA submission planned for 2H 2025
SHANGHAI, May 16, 2025 /PRNewswire/... |
| 15.05.2025 | Vivo Capital: Public Fund Closed With Over $740 Million In Commitments | Vivo Capital—a leading global investment firm focused exclusively on healthcare and life sciences—announced it has closed the third cycle of its Vivo Opportunity Fund and its affiliates with over $740 million in commitments. The Public Fund... |
| 29.04.2025 | Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024)
~25,000 prescriptions filled in Q1 2025
Q1 2025 revenue exceeds operating expenses excluding non-cash charges
Conference call ... |
| 15.04.2025 | Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, Apri... |
| 10.03.2025 |
Cramer’s Lightning Round: Merck is a buy | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Marvell Technology: “It’s a wild overreacti... |
| 27.02.2025 | Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
More prescriptions filled through February 2025 than in Q4 2024
Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuva... |
| 27.02.2025 | Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024
More prescriptions filled through February 2025 than in Q4 2024
Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuva... |
| 13.02.2025 | Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024... |
| 07.02.2025 | Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China | Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients
First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects
SHANGHAI, Feb. 7, 2025... |
| 19.11.2024 | Verona Pharma Announces December 2024 Investor Conference Participation | LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:
... |
| 05.11.2024 | Verona Pharma to Present at Jefferies London Healthcare Conference | LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference o... |
| 04.11.2024 | Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3
Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population
Pipeline exp... |
| 04.11.2024 | Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3
Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population
Pipeline exp... |
| 21.10.2024 | Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, No... |
| 30.09.2024 | Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024 | LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and two posters on analyses from its successful Phase 3 ENHANCE studies with ... |
| 30.09.2024 | Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024 | Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population
LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma... |
| 11.09.2024 | Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ensifentrine for the maintenance treatment of COPD | SHANGHAI, Sept. 11, 2024 /PRNewswire/ -- Nuance Pharma today announced it has completed the recruitment of patients for the ENHANCE-CHINA (NCT05743075) study, after planned number of patients have been successfully enrolled. The ENHANCE-CHI... |
| 05.09.2024 | Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024 | One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4
LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... |
| 05.09.2024 | Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024 | One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4
LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... |
| 08.08.2024 | Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update | OhtuvayreTM (ensifentrine) now available; patient shipments started
Strong balance sheet supports commercialization and pipeline expansion
Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE... |
| 30.07.2024 | Verona Pharma to Present at 44th Annual Canaccord Growth Conference | LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44th Annual Canaccord Growth Conference ... |
| 25.07.2024 | Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, Augu... |
| 25.07.2024 | Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, Augu... |
| 27.06.2024 | US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD | SHANGHAI, June 27, 2024 /PRNewswire/ -- Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announces the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chro... |
| 26.06.2024 | Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine) | Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients
First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects
Conference call tomorrow at 8:30 a.m. ED... |
| 09.05.2024 | Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS | - |
| 02.05.2024 | Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 | PDUFA Target Action Date of June 26, 2024
Eight posters including two oral presentations support potential of ensifentrine,
an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4
LONDON and RALEIGH, N.C., May 02, 202... |
| 29.02.2024 | Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | PDUFA Target Action Date for ensifentrine of June 26, 2024
Commercialization preparations advance
Strong balance sheet supports commercialization and Company's growth
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH... |
| 20.07.2023 | Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update | /EIN News/ -- LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it wil... |
| 28.06.2023 | Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD | SHANGHAI, June 28, 2023 /PRNewswire/ -- Nuance Pharma announces its partner, Verona Pharma plc (Nasdaq: VRNA), has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of e... |
| 27.06.2023 | Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD | /EIN News/ -- LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US Food and Drug Administration ... |
| 24.05.2023 | Verona Pharma to Present at Jefferies Healthcare Conference | /EIN News/ -- LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the Jefferies Healthcare Confe... |
| 02.05.2023 | Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023 | 12 Abstracts and one Symposium further support potential of ensifentrine,
a first-in-class, selective, dual inhibitor of PDE3 and PDE4
Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST
LONDON and RALEIGH, N.C., May 02, 2023 (GLOBE NEW... |
| 07.04.2023 | Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD") | SHANGHAI, April 7, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD"... |
| 07.04.2023 | Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD") | SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD"... |
| 20.12.2022 | Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD | Statistically significant improvements in lung function, symptoms and quality of life
36% reduction in rate of exacerbations over 24 weeks
Well tolerated safety profile over 48 weeks
NDA submission planned for 1H 2023
Conference call today ... |
| 09.11.2022 | Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update | /EIN News/ -- Access to up to $400 million expected to provide cash runway through at least 2025
Top-line Phase 3 ENHANCE-1 data expected around the end of 2022
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C.... |
| 26.10.2022 | Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its f... |
| 17.10.2022 | Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance | LONDON and RALEIGH, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it has entered into a debt financing facility (“debt facility”) providing the Company with access to ... |
| 29.08.2022 | Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference | LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the H.C. Wainwright 24th Annual Global Inve... |
| 24.08.2022 | Verona Pharma strengthens commercialization leadership team | LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, continues its preparation for comme... |
| 19.08.2022 | Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China | SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinic... |
| 19.08.2022 | Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China | SHANGHAI, Aug. 19, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinic... |
| 19.08.2022 | Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China | LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, ... |
| 19.08.2022 | Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China | LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc VRNA ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development... |
| 15.08.2022 | Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs | LONDON and RALEIGH, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the closing of its ... |
| 10.08.2022 | Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering | LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the pricing of its ... |
| 09.08.2022 | Verona Pharma plc Announces Proposed Underwritten Public Offering | LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwri... |
| 09.08.2022 | Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD | Statistically significant improvements in key measures of lung function
42% reduction in rate of exacerbations over 24 weeks
Well tolerated with safety results similar to placebo
Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
LONDON... |
| 09.08.2022 | Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update | Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD
Top-line Phase 3 ENHANCE-1 data expected around the end of 2022
Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
LONDON a... |
| 08.08.2022 | Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD | LONDON and RALEIGH, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will re... |
| 29.07.2022 | Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| 09.06.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD | LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed pa... |
| 06.06.2022 | Verona Pharma to Host KOL Event on June 16, 2022 | LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), today announces it will host an in-person KOL event for analysts and investors on Thursday, June 16, 2022, at 8:00 AM ET, in New... |
| 25.05.2022 | Verona Pharma to Present at Jefferies Healthcare Conference | LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a company overview at the Jefferies Healthcare Con... |
| 09.05.2022 | Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022 | LONDON and RALEIGH, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of an abstract demonstrati... |
| 04.05.2022 | Verona Pharma Announces May 2022 Investor Conference Participation | LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022:
LifeSci Partners Virtual Immunology & Inflam... |
| 03.05.2022 | Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update | Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022
James Brady joined the Board as Non-Executive Director
Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
LONDON and RALEIGH, N.C., May 03, 2022 (GLOBE NEWSWIRE) ... |
| 19.04.2022 | Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results... |
| 14.03.2022 | James Brady Joins Verona Pharma as Non-Executive Director | LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces Mr. James Brady has joined the board as a... |
| 03.03.2022 | Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update | Phase 3 ENHANCE program on track to report top-line COPD data in 2022
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or t... |
| 17.02.2022 | Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| 24.01.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD | Top-line Data Expected in the Third Quarter of 2022
LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respi... |
| 24.01.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD | LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed pa... |
| 05.01.2022 | Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset | ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022
ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022
LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... |
| 05.01.2022 | Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset | ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022
ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022
LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... |
| 04.01.2022 | Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference | LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., Preside... |
| 04.01.2022 | Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference | LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., Preside... |
| 16.12.2021 | Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction | LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces ensifentrine met all safety objectiv... |
| 16.12.2021 | Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction | Study Supports Ongoing Phase 3 Program and Planned NDA Submission
LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respirat... |
| 09.11.2021 | Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update | Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected to complete around year-end 2021
ENHANCE Phase 3 program on track to report top-line data in 2022
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C.,... |
| 01.11.2021 | Verona Pharma Announces November 2021 Investor Conference Participation | LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., Preside... |
| 01.11.2021 | Verona Pharma Announces November 2021 Investor Conference Participation | LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., Preside... |
| 26.10.2021 | Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| 13.10.2021 | Verona Pharma : to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021 | Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations
LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical compan... |
| 13.10.2021 | Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021 | LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of Phase 2 data demonstra... |
| 05.08.2021 | Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update | ENHANCE Phase 3 program on track to report top-line data in 2022
Up to $219 million strategic collaboration with Nuance Pharma in Greater China
Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
LONDON and RALEIGH, N.C., Aug. 05, 2021 (... |
| 27.07.2021 | Verona Pharma Announces August 2021 Virtual Investor Conference Participation | LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., Preside... |
| 22.07.2021 | Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| 10.06.2021 | Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China | LONDON and RALEIGH, N.C., and SHANGHAI, June 10, 2021 /PRNewswire/ -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma") and Nuance Pharma Limited ("Nuance Pharma"), today announce that the companies have entered into an... |
| 25.05.2021 | VERONA PHARMA PLC
Verona Pharma to Present at Jefferies Virtual Healthcare Conference | LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Off... |
| 04.05.2021 | VERONA PHARMA PLC
Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference | LONDON and RALEIGH, N.C., May 04, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces three abstracts highlighting new analyses f... |
| 29.04.2021 | VERONA PHARMA PLC
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update | ENHANCE Phase 3 program enrollment continues on track to complete in 2H21
Board strengthened with NED appointment of Lisa Deschamps
Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSW... |
